1. Home
  2. AVDL vs SRPT Comparison

AVDL vs SRPT Comparison

Compare AVDL & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVDL
  • SRPT
  • Stock Information
  • Founded
  • AVDL 2015
  • SRPT 1980
  • Country
  • AVDL Ireland
  • SRPT United States
  • Employees
  • AVDL N/A
  • SRPT N/A
  • Industry
  • AVDL Biotechnology: Pharmaceutical Preparations
  • SRPT Biotechnology: Pharmaceutical Preparations
  • Sector
  • AVDL Health Care
  • SRPT Health Care
  • Exchange
  • AVDL Nasdaq
  • SRPT Nasdaq
  • Market Cap
  • AVDL 1.8B
  • SRPT 1.9B
  • IPO Year
  • AVDL 1996
  • SRPT 1997
  • Fundamental
  • Price
  • AVDL $23.50
  • SRPT $19.09
  • Analyst Decision
  • AVDL Buy
  • SRPT Hold
  • Analyst Count
  • AVDL 9
  • SRPT 30
  • Target Price
  • AVDL $18.06
  • SRPT $35.93
  • AVG Volume (30 Days)
  • AVDL 5.5M
  • SRPT 6.1M
  • Earning Date
  • AVDL 11-04-2025
  • SRPT 11-03-2025
  • Dividend Yield
  • AVDL N/A
  • SRPT N/A
  • EPS Growth
  • AVDL N/A
  • SRPT N/A
  • EPS
  • AVDL N/A
  • SRPT N/A
  • Revenue
  • AVDL $248,517,000.00
  • SRPT $2,413,715,000.00
  • Revenue This Year
  • AVDL $64.21
  • SRPT $10.20
  • Revenue Next Year
  • AVDL $30.80
  • SRPT N/A
  • P/E Ratio
  • AVDL N/A
  • SRPT N/A
  • Revenue Growth
  • AVDL 79.88
  • SRPT 47.15
  • 52 Week Low
  • AVDL $6.38
  • SRPT $10.42
  • 52 Week High
  • AVDL $23.57
  • SRPT $138.81
  • Technical
  • Relative Strength Index (RSI)
  • AVDL 91.85
  • SRPT 45.14
  • Support Level
  • AVDL $18.74
  • SRPT $17.50
  • Resistance Level
  • AVDL $19.00
  • SRPT $18.63
  • Average True Range (ATR)
  • AVDL 0.25
  • SRPT 1.46
  • MACD
  • AVDL 0.20
  • SRPT -0.42
  • Stochastic Oscillator
  • AVDL 98.80
  • SRPT 40.34

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

Share on Social Networks: